CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank

Maarten H Geurts, Eyleen de Poel, Gimano D Amatngalim, Rurika Oka, Fleur M Meijers, Evelien Kruisselbrink, Peter van Mourik, Gitte Berkers, Karin M de Winter-de Groot, Sabine Michel, Danya Muilwijk, Bente L Aalbers, Jasper Mullenders, Sylvia F Boj, Sylvia W F Suen, Jesse E Brunsveld, Hettie M Janssens, Marcus A Mall, Simon Y Graeber, Ruben van BoxtelCornelis K van der Ent, Jeffrey M Beekman, Hans Clevers

Research output: Contribution to journal/periodicalArticleScientificpeer-review

117 Citations (Scopus)


Adenine base editing (ABE) enables enzymatic conversion from A-T into G-C base pairs. ABE holds promise for clinical application, as it does not depend on the introduction of double-strand breaks, contrary to conventional CRISPR/Cas9-mediated genome engineering. Here, we describe a cystic fibrosis (CF) intestinal organoid biobank, representing 664 patients, of which ~20% can theoretically be repaired by ABE. We apply SpCas9-ABE (PAM recognition sequence: NGG) and xCas9-ABE (PAM recognition sequence: NGN) on four selected CF organoid samples. Genetic and functional repair was obtained in all four cases, while whole-genome sequencing (WGS) of corrected lines of two patients did not detect off-target mutations. These observations exemplify the value of large, patient-derived organoid biobanks representing hereditary disease and indicate that ABE may be safely applied in human cells.

Original languageEnglish
Pages (from-to)503-510.e7
JournalCell Stem Cell
Issue number4
Publication statusPublished - 02 Apr 2020


Dive into the research topics of 'CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank'. Together they form a unique fingerprint.

Cite this